ArticlePathogens (Basel, Switzerland)2021

Sustained Antiviral and Liver Protection by a Nasal Therapeutic Vaccine (NASVAC, Containing Both HBsAg and HBcAg) in Patients with Chronic Hepatitis B: 2-Year Follow-Up of Phase III Clinical Trial.

Sheikh Mohammad Fazle Akbar et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.